Development of high affinity monobodies recognizing SARS-CoV-2 antigen

Yushen Du(University of California, Los Angeles), Ren Sun(University of California, Los Angeles)

Research Square (Research Square)

April 28, 2020

10.21203/rs.3.rs-25828/v1

Cited by 9

Related Papers

Clofazimine broadly inhibits coronaviruses including SARS-CoV-2

|Nature|2021|211

CCL21-DC in situ vaccination in murine NSCLC overcomes resistance to immunotherapy and generates systemic tumor-specific immunity

|Journal for ImmunoTherapy of Cancer|2023|30

Clofazimine is a broad-spectrum coronavirus inhibitor that antagonizes SARS-CoV-2 replication in primary human cell culture and hamsters

|Research Square|2020|22

Interferon Epsilon Loss Is Elusive 9p21 Link to Immune-Cold Tumors, Resistant to Immune Checkpoint Therapy, and Endogenous CXCL9/10 Induction

|Journal of Thoracic Oncology|2024|12